Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNγ Administration
- Authors: Petinati N.A.1, Kapranov N.M.1, Bigil’deev A.E.1, Popova M.D.1, Davydova Y.O.1, Gal’tseva I.V.1, Drize N.I.1, Kuz’mina L.A.1, Parovichnikova E.N.1, Savchenko V.G.1
-
Affiliations:
- Hematology Research Center, Ministry of Health Care of the Russian Federation
- Issue: Vol 163, No 2 (2017)
- Pages: 230-234
- Section: Microbiology and Immunology
- URL: https://journals.rcsi.science/0007-4888/article/view/238778
- DOI: https://doi.org/10.1007/s10517-017-3773-3
- ID: 238778
Cite item
Abstract
We studied changes in the population of human multipotent mesenchymal stromal cells activated by IFNγ. The cells were cultured under standard conditions; IFNγ was added in various concentrations for 4 h or over 2 passages. It was shown that the total cell production significantly decreased after long-term culturing with IFNγ, but 4-h exposure did not affect this parameter. After 4-h culturing, the expression levels of IDO1, CSF1, and IL-6 increased by 300, 7, and 2.4 times, respectively, and this increase persisted 1 and 2 days after removal of IFNγ from the culture medium. The expression of class I and II MHC (HLA) on cell surface practically did not change immediately after exposure to IFNγ, but during further culturing, HLA-ABC (MHC I) and HLA-DR (MHC II) expression significantly increased, which abolished the immune privilege in these cells, the property allowing clinical use of allogenic multipotent mesenchymal stromal cells. Multipotent mesenchymal stromal cells can suppress proliferation of lymphocytes. The degree of this suppression depends on individual properties of multipotent mesenchymal stromal cell donor. Treatment with IFNγ did not significantly affect the intensity of inhibition of lymphocyte proliferation by these cells.
About the authors
N. A. Petinati
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
N. M. Kapranov
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
A. E. Bigil’deev
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
M. D. Popova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
Yu. O. Davydova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
I. V. Gal’tseva
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
N. I. Drize
Hematology Research Center, Ministry of Health Care of the Russian Federation
Author for correspondence.
Email: ndrize@yandex.ru
Russian Federation, Moscow
L. A. Kuz’mina
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
E. N. Parovichnikova
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow
V. G. Savchenko
Hematology Research Center, Ministry of Health Care of the Russian Federation
Email: ndrize@yandex.ru
Russian Federation, Moscow